A Pigmented Intraventricular Tumor in a 10-Year-Old Girl: A Diagnostic Conundrum between Meningeal Melanocytoma and Melanotic Ependymoma with Integrated DNA Methylation and Next-Generation Sequencing Findings
This paper reports a rare case of a pigmented intraventricular tumor in a 10-year-old girl that was diagnostically challenging between meningeal melanocytoma and melanotic ependymoma but was ultimately classified as a WHO grade 1 meningeal melanocytoma through integrated histopathology, immunohistochemistry, and negative genomic findings following gross-total resection.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Inside the human brain, the ventricles are fluid-filled chambers that act as a quiet reservoir, cushioning the delicate tissue of the mind. Occasionally, a growth can appear within these spaces, and when that growth is darkly colored, it presents a unique puzzle for doctors. The darkness usually comes from melanin, the same pigment that gives skin its color. In the brain, a mass containing this pigment could be one of two very different things: a tumor arising from the lining of the brain itself, or a rare variant of a tumor that normally grows from the cells lining the ventricles. Distinguishing between them is critical because the two conditions require different treatments and carry different long-term risks. One is generally a slow-growing, benign mass that can often be cured with surgery alone, while the other is a more complex glial tumor that might need additional therapy.
This story begins with a ten-year-old girl who arrived at a hospital in Chengdu, China, complaining of headaches and nausea that were worse in the morning. These symptoms suggested that pressure was building up inside her skull. Scans of her brain revealed a distinct, dark mass sitting in the trigone, a specific corner of the left ventricle. The tumor was rich in blood vessels and showed signs of calcification. When surgeons removed it, they found a soft, friable, and deeply pigmented mass that was clearly separate from the surrounding brain tissue. The operation was successful, and the entire tumor was taken out. However, the mystery did not end in the operating room. When pathologists examined the tissue under a microscope, they faced a difficult choice. The cells were arranged in a way that looked like a specific type of glial tumor called a melanotic ependymoma, but the overall appearance of the cells and their lack of certain markers suggested a different diagnosis: a meningeal melanocytoma, a tumor of the brain's lining.
To solve this diagnostic riddle, the medical team brought together experts from two different institutions and employed the most advanced genetic tools available. One pathologist, working at the hospital where the surgery took place, noted that the tumor cells formed ring-like structures around blood vessels, a feature often seen in ependymomas. However, the cells themselves did not show the typical markers of glial cells, and the report concluded that a melanotic ependymoma could not be ruled out. A second team of specialists, reviewing the same slides independently, saw a different picture. They described the cells as bland and round, filled with pigment and surrounded by immune cells that had eaten up the pigment debris. These experts leaned heavily toward a diagnosis of meningeal melanocytoma, a much rarer and generally less aggressive tumor.
The team then turned to molecular science to see if the DNA could provide a definitive answer. They performed a genome-wide analysis of the tumor's chemical methylation patterns, a technique that acts like a fingerprint for different types of brain tumors. The results were inconclusive; the tumor did not match the known fingerprint of a melanotic ependymoma, nor did it perfectly match the profile of a typical meningeal melanocytoma. It landed in a gray area, closest to a completely different type of tumor that did not fit the patient's age or symptoms. Next, they sequenced the tumor's genes to look for specific mutations that drive these cancers. They found no mutations in the genes typically associated with melanocytic tumors, nor did they find the genetic signatures common in ependymomas. The tumor had a very low number of genetic errors and a balanced set of chromosomes, suggesting it was a stable, slow-growing lesion rather than an aggressive cancer.
Weighing all the evidence, the researchers concluded that the tumor was most likely a circumscribed meningeal melanocytoma, classified as a low-grade, benign growth. The case for this diagnosis rested on the fact that the tumor cells lacked the specific markers of glial tumors, showed signs of being derived from the brain's lining, and possessed a genetic profile consistent with a benign, non-aggressive mass. While the ring-like arrangement of cells kept the possibility of a melanotic ependymoma on the table as a formal alternative, the weight of the genetic and microscopic evidence tipped the scale. The girl was discharged with a plan for close monitoring rather than radiation or chemotherapy, as the tumor had been completely removed and appeared to be low-risk. Six months later, follow-up scans showed no sign of the tumor returning.
This case highlights the complexity of diagnosing rare brain tumors in children. It demonstrates that even when a tumor looks like one thing under a microscope, advanced genetic testing can reveal a different reality. The researchers noted that this might be the first documented case of this specific type of pigmented tumor occurring inside a ventricle in a child. While the diagnosis was not straightforward, the integration of imaging, microscopic examination, and genetic sequencing allowed the team to reach a confident conclusion. The girl's story serves as a reminder that in modern medicine, the answer often lies not in a single test, but in the careful synthesis of many different lines of evidence.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.